STANDARD VERSUS BIOFILM SUSCEPTIBILITY TESTING IN CYSTIC FIBROSIS

囊性纤维化的标准与生物膜敏感性测试

• 批准号: 7377022
• 负责人: RICHARD C AHRENS
• 金额: $ 0.5万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-03-01 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7377022
• 关键词: STANDARD; VERSUS; BIOFILM; SUSCEPTIBILITY; TESTING

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. People with cystic fibrosis (CF) often have lung infections, which occur repeatedly or worsen over time. The lung infections are caused by bacteria. One of the more common bacteria in the lungs of people with CF is Pseudomonas aeruginosa (Pa). Treatment with antibiotics is used to stop or slow down the growth of the Pa. To help decide which antibiotics to use, samples of patients sputum are sent to the laboratory. The laboratory determines what antibiotics appear to work best to treat the Pa infection. This is called antibiotic sensitivity testing. Sometimes the antibiotic treatment is not as effective as we would hope. One reason may be that Pa in the lungs grows slowly in a thick mucus called biofilm. The current ways that we test for antibiotic sensitivity do not account for this biofilm. However, a new type of antibiotic susceptibility testing, called biofilm testing, has been developed. Because it better mimics what the bacteria is doing in the lungs, it may be more useful in choosing antibiotics to treat Pa lung infections in patients with CF. The purpose of this study is to compare the standard antibiotic sensitivity test to the biofilm sensitivity test in people with CF and Pa. Participants will receive 14 days of antibiotic therapy, based on the results of one of the sensitivity tests. Which test is used is decided totally by chance. At the end of the therapy, the amount of Pa in the lung will be measured, and we will see if the antibiotics selected by the biofilm sensitivity reduced the amount of Pa in the lungs more than the antibiotics selected by the standard sensitivity test.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中出现。列出的机构是中心的机构，不一定是研究者的机构。囊性纤维化 (CF) 患者通常会出现肺部感染，这种感染会反复发生或随着时间的推移而恶化。肺部感染是由细菌引起的。 CF 患者肺部最常见的细菌之一是铜绿假单胞菌 (Pa)。抗生素治疗用于阻止或减缓 Pa 的生长。为了帮助决定使用哪种抗生素，患者的痰样本会被送往实验室。实验室确定哪些抗生素最适合治疗 Pa 感染。这称为抗生素敏感性测试。有时抗生素治疗并不像我们希望的那样有效。原因之一可能是肺中的 Pa 在称为生物膜的浓稠粘液中缓慢生长。我们目前测试抗生素敏感性的方法并未考虑到这种生物膜。然而，一种新型的抗生素敏感性测试，称为生物膜测试，已经被开发出来。由于它能更好地模拟细菌在肺部的作用，因此在选择抗生素治疗 CF 患者的肺部感染时可能更有用。本研究的目的是比较 CF 和 Pa 患者的标准抗生素敏感性测试与生物膜敏感性测试。参与者将根据其中一项敏感性测试的结果接受 14 天的抗生素治疗。使用哪种测试完全是偶然决定的。治疗结束时，将测量肺部 Pa 量，我们将观察生物膜敏感性选择的抗生素是否比标准敏感性测试选择的抗生素减少肺部 Pa 量更多。